TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25503447

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise (3 times per week for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 29
Study: 23458393

Group type: EXPERIMENTAL
Intervention: ALA-IPL-PDT
Number of subjects: 41

Group type: COMPARATOR
Intervention: IPL
Number of subjects: 41
Study: 21368422

Group type: EXPERIMENTAL
Intervention: Systematic self-management education
Number of subjects: 248

Group type: COMPARATOR
Intervention: Routine community education
Number of subjects: 248
Study: 19548412

Group type: EXPERIMENTAL
Intervention: Breeze self‐adhesive resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxcem self‐adhesive resin cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fuji glass‐ionomer cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fleck's zinc phosphate cement
Number of subjects: 40
Study: 17822337

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX; ≤1.8mg/kg per day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 142
Study: 15018291

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.3 mg orally 7 hours prior to landing)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 25
Study: 11336591

Group type: EXPERIMENTAL
Intervention: Benzoporphin derivative (BPD) - verteporfin (Visudyne)
Number of subjects: 500000
Study: 9716055

Group type: COMPARATOR
Intervention: Conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose therapy (identical treatment but with an additional high-dose regimen and peripheral-blood progenitor-cell support after the fourth FE120C course)
Number of subjects: 97
Study: 7984328

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta
Number of subjects: 0
Study: 2721109

Group type: EXPERIMENTAL
Intervention: 337.5 mg/day propafenone
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 450 mg/day propafenone
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 675 mg/day propafenone
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: 900 mg/day propafenone
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 127471

Group type: EXPERIMENTAL
Intervention: Ro 6-0787 combined with penicillin therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ro 6-0787 alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined Ro 6-0787-penicillin treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ro 6-0787
Number of subjects: 90
Study: 31658975

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 501

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL
Number of subjects: 501
Study: 30357438

Group type: EXPERIMENTAL
Intervention: RGB-10 (biosimilar teriparatide)
Number of subjects: 54
Study: 28344144

Group type: EXPERIMENTAL
Intervention: Patient-specific tailored intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 145
Study: 25923852

Group type: EXPERIMENTAL
Intervention: d-cycloserine (50 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: d-cycloserine (50 mg weekly)
Number of subjects: 20
Study: 23438932

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 149
Study: 21305238

Group type: EXPERIMENTAL
Intervention: Back school + exercise + physical treatment modalities
Number of subjects: 146

Group type: COMPARATOR
Intervention: Exercise + physical treatment modalities
Number of subjects: 146
Study: 19325134

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 33690
Study: 17702700

Group type: EXPERIMENTAL
Intervention: EMG-triggered feedback combined with movement imagery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional electrostimulation
Number of subjects: 27
Study: 15167505

Group type: EXPERIMENTAL
Intervention: Attitudes, perceived partner approval, self-pride, parental pride
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Attitudes, intentions to engage in sex in the next 3 months, self-pride, parental pride, goals, partner approval
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Attitudes, subjective norms, self-efficacy, partner and parental approval, impulse control beliefs
Number of subjects: 141
Study: 11820343

Group type: EXPERIMENTAL
Intervention: Specialist psychosexual counselling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 9514451

Group type: EXPERIMENTAL
Intervention: Collagen hemostatic puncture closure device
Number of subjects: 304

Group type: COMPARATOR
Intervention: Manual pressure control group
Number of subjects: 304
Study: 8000036

Group type: EXPERIMENTAL
Intervention: Glutamate-arginine salt (AGs)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 3
Study: 30620371

Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg
Number of subjects: 440
Study: 29286586

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Enriched supportive therapy (EST)
Number of subjects: 54
Study: 27684809

Group type: EXPERIMENTAL
Intervention: Glucose 75% solution
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.2% diluted in glucose 70%
Number of subjects: 96
Study: 24158271

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) combined with best medical therapy (BMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy (BMT) alone
Number of subjects: 0
Study: 22524590

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Blood Glucose Monitoring (BGM)
Number of subjects: 0
Study: 19653746

Group type: EXPERIMENTAL
Intervention: Manipulated stimulus-onset asynchrony (SOA) between successive items in the stream
Number of subjects: 0
Study: 17447865

Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study: 16291717

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (ethinyl estradiol 35 microg and varying doses of norgestimate: 0.18, 0.215, and 0.25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No triphasic oral contraceptive (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive
Number of subjects: 10
Study: 11896479

Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 6 mg apomorphine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 150 mg papaverine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine + 6 mg apomorphine + 150 mg papaverine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 44
Study: 9695196

Group type: EXPERIMENTAL
Intervention: Prospective individual matching procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional randomized block design
Number of subjects: 0
Study: 7650334

Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy (360‐700 MU/square meter of body surface, 2 or 3 times weekly for 12 to 24 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Higher histological activity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lower percentage of HBcAg‐stained hepatocytes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aspartate amino transferase and alanine aminotransferase levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase peak prior to serum HBV‐DNA clearance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Percentage of HBcAg stained cells with alanine aminotransferase levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Percentage of HBcAg stained cells with histological activity index
Number of subjects: 50
Study: 2516669

Group type: EXPERIMENTAL
Intervention: R/5 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 3 months)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: R/7 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 5 months)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Z/7 (same regimen as R/7 but without rifampicin)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Initial drug resistance to streptomycin or isoniazid or both
Number of subjects: 503
Study: 5023913

Group type: EXPERIMENTAL
Intervention: Sterile fusidic acid gel introduced into the cavity on one occasion only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily superficial dressings impregnated with sodium fusidate ointment
Number of subjects: 0
Study: 31858912

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NSAIDs (Naproxen 1 gm/day or Etoricoxib 120 mg/day)
Number of subjects: 60
Study: 30639273

Group type: EXPERIMENTAL
Intervention: Sequential combination training (SEQ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 30
Study: 28459931

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (25% of energy needs on fast days; 125% of energy needs on feast days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily calorie restriction (75% of energy needs every day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily calorie restriction
Number of subjects: 100
Study: 25398725

Group type: EXPERIMENTAL
Intervention: Dr Kawashima's Brain Training (DKBT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 35
Study: 23826125

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 130
Study: 21716078

Group type: EXPERIMENTAL
Intervention: lamivudine-containing ART
Number of subjects: 106

Group type: COMPARATOR
Intervention: non-HBV-active drugs
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HIV/HBV-coinfected participants
Number of subjects: 106

Group type: COMPARATOR
Intervention: HIV monoinfected participants
Number of subjects: 106
Study: 18287793

Group type: EXPERIMENTAL
Intervention: Zinc only (n = 11)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zinc + vitamin E (n = 12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zinc + vitamins E + C (n = 14)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Zinc deficiency (in vitro experiment)
Number of subjects: 45
Study: 17171204

Group type: EXPERIMENTAL
Intervention: 45 mg of elemental iron weekly for 6 months (anemic children)
Number of subjects: 378

Group type: COMPARATOR
Intervention: No intervention (non-anemic children)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 45 mg of elemental iron weekly for 6 months (both treated groups)
Number of subjects: 378
Study: 14513188

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 11094242

Group type: EXPERIMENTAL
Intervention: Prophylactic intrapartum amnioinfusion
Number of subjects: 1533

Group type: COMPARATOR
Intervention: Control group (no amnioinfusion)
Number of subjects: 1533
Study: 9142432

Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milrinone and enoximone
Number of subjects: 0
Study: 1582642

Group type: EXPERIMENTAL
Intervention: Phytogenic preparation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ointment containing synthetic substances
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ointment containing synthetic substances with corticoid
Number of subjects: 90
Study: 3987543

Group type: EXPERIMENTAL
Intervention: Felodipine (0.25, 0.75, 1.5 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Verapamil (2.0, 4.0, 8.0 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg) after felodipine and verapamil
Number of subjects: 9
Study: 29284287

Group type: EXPERIMENTAL
Intervention: rAd-p53 therapy combined with radiotherapy and hyperthermia (p53 group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Radiotherapy and hyperthermia alone (control group)
Number of subjects: 71
Study: 27412888

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25343963

Group type: EXPERIMENTAL
Intervention: Oral loading dose of Vitamin D (500,000 IU) followed by an oral dose of 50,000 IU of Vitamin D monthly for 2 years
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Oral high‐dose vitamin D therapy
Number of subjects: 75
Study: 23756453

Group type: EXPERIMENTAL
Intervention: Goal-Directed Therapy (GDT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Fluid Therapy (Control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Orthostatic Intolerance (OI)
Number of subjects: 42
Study: 20806388

Group type: EXPERIMENTAL
Intervention: GreenLight HPS laser (532 nm, 120 W)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Diode laser (980 nm, 200 W)
Number of subjects: 139
Study: 18162183

Group type: EXPERIMENTAL
Intervention: Left‐on unilateral STN DBS
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Right‐on unilateral STN DBS
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bilateral STN DBS
Number of subjects: 49
Study: 15982505

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg co-administered with simvastatin 10 mg or 20 mg
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo co-administered with simvastatin 10 mg or 20 mg
Number of subjects: 372
Study: 12626793

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (8-week adjunctive psychological intervention)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Routine medical management (Control group)
Number of subjects: 53
Study: 11097197

Group type: EXPERIMENTAL
Intervention: Cocaine (80 mg/70 kg p.o.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cocaine and Placebo (both)
Number of subjects: 35
Study: 9206191

Group type: EXPERIMENTAL
Intervention: Mifepristone 150 mg in separated doses followed by PG05 1 mg vaginally
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Mifepristone 200 mg in single dose followed by PG05 1 mg vaginally
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 4500
Study: 1392491

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 60
Study: 3919522

Group type: EXPERIMENTAL
Intervention: High phosphate group (60-80 mmol phosphate/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low phosphate group (7.5 mmol phosphate from fat emulsion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard nutrition programme
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phosphate supplementation (80 mmol phosphate/day)
Number of subjects: 30
Study: 29125679

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (TXA) 500 mg in 5 mL
Number of subjects: 124

Group type: COMPARATOR
Intervention: Anterior Nasal Packing (ANP)
Number of subjects: 124
Study: 28471579

Group type: EXPERIMENTAL
Intervention: Spa therapy plus pharmacological treatment for 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacological treatment alone
Number of subjects: 0
Study: 25109581

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional rotating handpiece
Number of subjects: 10
Study: 22533654

Group type: EXPERIMENTAL
Intervention: AZL‐M 40 mg and CLD 25 mg
Number of subjects: 1714

Group type: COMPARATOR
Intervention: AZL‐M 80 mg
Number of subjects: 1714

Group type: COMPARATOR
Intervention: CLD 25 mg
Number of subjects: 1714
Study: 20667790

Group type: EXPERIMENTAL
Intervention: Thrombolysis within 3-4.5 hours after stroke onset
Number of subjects: 23942

Group type: COMPARATOR
Intervention: Thrombolysis within 3 hours
Number of subjects: 23942
Study: 17851130

Group type: EXPERIMENTAL
Intervention: SLN resection followed by conventional ALND
Number of subjects: 5611

Group type: COMPARATOR
Intervention: SLN resection alone
Number of subjects: 5611
Study: 16109117

Group type: EXPERIMENTAL
Intervention: Divalproex 500 mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Divalproex 1000 mg/day
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Divalproex 1500 mg/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12145720

Group type: EXPERIMENTAL
Intervention: Levofloxacin (750 mg once per day)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Ticarcillin-clavulanate (3.1 g iv every 4-6 hours) followed by amoxicillin-clavulanate (875 mg orally every 12 hours)
Number of subjects: 399
Study: 11026121

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMP) with adjunctive manual-guided psychosocial group interventions
Number of subjects: 302

Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMP)
Number of subjects: 302
Study: 9109829

Group type: EXPERIMENTAL
Intervention: Thin carrot (2 cm length, 2 cm width, 0.5 cm thickness)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cheese (2 cm length, 2 cm width, 0.5 cm thickness)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thickest sample (1.5 cm thickness)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Carrot (thin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cheese (thin)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thickest sample
Number of subjects: 9
Study: 8477058

Group type: EXPERIMENTAL
Intervention: Regimen S1 (cranial irradiation 18 Gy and intrathecal chemotherapy starting at 5 weeks)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Regimen S2 (cranial irradiation and intrathecal chemotherapy starting at 24 weeks)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 207
Study: 3762903

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intense exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) and intense exercise (combined)
Number of subjects: 0
Study: 31313062

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Combination of CBT and sertraline
Number of subjects: 279
Study: 29523651

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (1 mA, 20 minutes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 58
Study: 26612882

Group type: EXPERIMENTAL
Intervention: SafeR
Number of subjects: 646

Group type: COMPARATOR
Intervention: DDD
Number of subjects: 646
Study: 24777475

Group type: EXPERIMENTAL
Intervention: Female bully with female victim
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Male bully with female victim
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Female bully with male victim
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Male bully with male victim
Number of subjects: 437
Study: 23192720

Group type: EXPERIMENTAL
Intervention: Compelled body weight shift (CBWS) therapy combined with physical therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Physical therapy (Control)
Number of subjects: 18
Study: 20384426

Group type: EXPERIMENTAL
Intervention: Alcohol (0.84 g/kg for men, 0.76 g/kg for women)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 130
Study: 18840807

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise (n=36)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Health education control program (n=30)
Number of subjects: 66
Study: 15818329

Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional immunosuppressive treatment
Number of subjects: 4
Study: 12612717

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg/day
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 57
Study: 10342550

Group type: EXPERIMENTAL
Intervention: Oral albuterol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 8546441

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 1790086

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 60
Study: 31159537

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bupivacaine (BUP)
Number of subjects: 54
Study: 28602413

Group type: EXPERIMENTAL
Intervention: Hormone Therapy and Radiation Therapy (HT-RT)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 722
Study: 25542519

Group type: EXPERIMENTAL
Intervention: Topical artificial tears
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%/tobramycin 0.3%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (age‐matched)
Number of subjects: 60
Study: 23421327

Group type: EXPERIMENTAL
Intervention: Wash product (n = 159)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Water alone (n = 148)
Number of subjects: 307
Study: 20827284

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19820284

Group type: EXPERIMENTAL
Intervention: Solifenacin (5/10 mg)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739